Non-Opioid Pain Medication Is on FDA Fast Track for Review

The U.S. Food and Drug Administration has granted fast-track designation for tanezumab, a medication for the treatment of patients with chronic low back pain or osteoarthritis. The FDA’s fast-track designation is intended to speed the review of new therapies to treat serious conditions and fill unmet medical needs. If approved, tanezumab would be the first in a new class of non-opioid medications to treat chronic pain, according to Pfizer Inc. and Eli Lilly and Co., which are working together to develop the drug. Tanezumab is an antibody that binds to and inhibits nerve growth fa...